Last edition
News about Global Pharma
Lupin Gets Approval from FDA for Abacavir, Dolutegravir and Lamivudine Tablets
Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension, 60 mg/5 mg/30 mg, (RLD Triumeq PD) had an estimated annual sale of USD 1.3 million in the US.
Global Pharma | 06/12/2024 | By Aishwarya | 767
Lilly to Invest USD 3 Billion to Expand its Manufacturing Facility in Wisconsin
Lilly expects to add 750 highly skilled jobs to the current 100-plus workforce at this location.
Global Pharma | 06/12/2024 | By Aishwarya | 258
Phanes Secures Fast Track Designation for PT217 from FDA
PT217, a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD47, is being developed for the treatment of patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma, including neuroendocrine prostate cancer (NEPC).
Global Pharma | 05/12/2024 | By Aishwarya | 393
The expanded collaboration will leverage Orbit Discovery’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen Theragnostics’ expertise in radiopharmaceutical development and clinical translation.
Global Pharma | 04/12/2024 | By Aishwarya | 329
Martin Pharmaceuticals Gets Exclusive Rights from MTPC for Docarpamine
The Phase 2a open-label trial enrolled 16 patients with refractory ascites requiring regular large-volume paracentesis (LVP).
Global Pharma | 04/12/2024 | By Aishwarya | 534
Ampersand Capital Partners Launches Newly Branded Business Gannet BioChem
The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama.
Global Pharma | 03/12/2024 | By Aishwarya | 869
CBC Group Acquires UCB's Mature Product Portfolio in China
The acquisition marks another successful transaction under CBC's buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC's portfolio within the region's dynamic pharmaceutical market.
Global Pharma | 03/12/2024 | By Aishwarya | 763
Roche Announces Acquisition of Poseida Therapeutics
The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies.
Global Pharma | 03/12/2024 | By Aishwarya | 428
Brenntag, K+S to Expand its Business in High-Purity Salts for Pharma Applications
Brenntag will now distribute three of their salts in the pharmaceutical market: APISAL Sodium Chloride GMP grade (in pharmacopoeia quality, API), Potassium Chloride 99.9 percent KCl Ph. Eur., USP (API) and HD-NaCl (excipient grade).
Global Pharma | 03/12/2024 | By Aishwarya | 336
Allink Biotherapeutics Secures USD 42 Million Series A Financing Round
The financing round was led by Lanchi Ventures, a preeminent global early-stage technology investor known for backing breakthrough innovations, with participation from an elite syndicate of new investors.
Global Pharma | 02/12/2024 | By Aishwarya | 246
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy